MoonLake Immunotherapeutics
General ticker "MLTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.7B (TTM average)
MoonLake Immunotherapeutics does not follow the US Stock Market performance with the rate: -14.5%.
Estimated limits based on current volatility of 4.3%: low 12.93$, high 14.11$
Factors to consider:
- Total employees count: 100 (+100.0%) as of 2024
- Top business risk factors: Dependence on SLK, Market competition, Product safety concerns, Capital raising, Geopolitical risks
- Current price 44.4% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [26.99$, 61.10$]
- 2025-12-31 to 2026-12-31 estimated range: [19.97$, 47.19$]
Financial Metrics affecting the MLTX estimates:
- Negative: with PPE of -28.1 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.49 <= 0.33
- Positive: Shareholder equity ratio, % of 93.49 > 63.39
- Positive: -14.38 < Investing cash flow per share per price, % of -6.16
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
Short-term MLTX quotes
Long-term MLTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $65.06MM | $54.12MM | $143.09MM |
| Operating Income | $-65.06MM | $-54.12MM | $-143.09MM |
| Non-Operating Income | $0.59MM | $10.14MM | $22.13MM |
| R&D Expense | $42.05MM | $31.80MM | $112.77MM |
| Income(Loss) | $-64.47MM | $-43.98MM | $-120.96MM |
| Taxes | $0.04MM | $0.09MM | $0.28MM |
| Profit(Loss)* | $-49.97MM | $-36.01MM | $-118.94MM |
| Stockholders Equity | $48.90MM | $495.68MM | $446.83MM |
| Assets | $76.84MM | $526.54MM | $477.93MM |
| Operating Cash Flow | $-55.89MM | $-42.78MM | $-116.59MM |
| Capital expenditure | $0.02MM | $0.28MM | $0.52MM |
| Investing Cash Flow | $-32.34MM | $-25.18MM | $-205.60MM |
| Financing Cash Flow | $119.69MM | $479.70MM | $51.31MM |
| Earnings Per Share** | $-1.70 | $-0.73 | $-1.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.